Astex Signs a Multi-Year Discovery Collaboration with Cardiff University Medicines Discovery Institute to Identify New Drugs for Neurodegenerative Diseases
Shots:
- Cardiff University will receive R&D funding and is eligible to receive development and regulatory fees if drug compounds progress along with royalty on the sales of any approved products
- The collaboration will combine MDI’s drug discovery capabilities and the research expertise of Drs. Emyr Lloyd-Evans and Helen Waller-Evans in lysosomal biology with Astex’s fragment-based drug discovery platform to identify compounds that modulate lysosomal activity to develop new treatments for neurodegenerative diseases
- Additionally, the partnership also supports and advances research to transform the lives of neurodegenerative diseases patients
Ref: Astex | Image: Astex
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
